Free Trial

Nanobiotix 4/2/2025 Earnings Report

Nanobiotix logo
$3.39 -0.19 (-5.20%)
As of 04/2/2025 12:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nanobiotix EPS Results

Actual EPS
-$0.58
Consensus EPS
-$0.58
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Nanobiotix Revenue Results

Actual Revenue
$3.55 million
Expected Revenue
$3.55 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Nanobiotix Announcement Details

Quarter
Time
Before Market Opens

Conference Call Resources

Remove Ads

Nanobiotix Earnings Headlines

DOGE tax surprise
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.
See More Nanobiotix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nanobiotix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nanobiotix and other key companies, straight to your email.

About Nanobiotix

Nanobiotix (NASDAQ:NBTX), a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

View Nanobiotix Profile

More Earnings Resources from MarketBeat